European Heart Journal · 2024 · 18 citations · 16 references
MedicineCardiologyInternal MedicineEpidemiologic MethodsInterventional CardiologyOutcomes ResearchAcute Coronary Syndrome InterventionAcute Coronary SyndromesCardiovascular DiseaseCardiovascular RiskCoronary Artery DiseaseStrokeClinical Outcomes After Percutaneous Coronary InterventionCohort Study InvestigationHigh-risk Percutaneous Coronary Intervention
BACKGROUND AND AIMS: Patients with high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI) are at increased risk of not only bleeding, but also ischaemic events. This study aimed to determine the long-term relative risk of ischaemic and bleeding events in HBR patients. METHODS: This study was a nationwide cohort study, based on the Korean National Health Insurance Review and Assessment Service database. Patients diagnosed with stable angina or acute coronary syndrome and those who underwent PCI in Korea between 2009 and 2018 were included in the analysis. According to the Academic Research Consortium HBR criteria, the total population was divided into HBR and non-HBR groups. The co-primary outcomes were major bleeding events and ischaemic (composite of cardiac death, myocardial infarction, and ischaemic stroke) events. RESULTS: Among a total of 325 417 patients who underwent PCI, 66 426 patients (20.4%) had HBR. During the follow-up period, HBR patients had a higher risk for major bleeding events (23.9% vs. 8.9%, P < .001) and ischaemic events (33.8% vs. 14.4%, P < .001). However, the impact of HBR was significant for major bleeding events [hazard ratio (HR) 3.12, 95% confidence interval (CI) 3.04-3.21, P < .001] and for ischaemic events (HR 2.50, 95% CI 2.45-2.56, P < .001). The HBR group was also associated with a greater risk of all-cause mortality (HR 3.73, 95% CI 3.66-3.79, P < .001). The average annual rate of major bleeding events within the first year after PCI was 5.5% for a single major criterion, and 2.9% for a single minor criterion. CONCLUSIONS: Among patients undergoing PCI, those with HBR were at increased long-term risk for both bleeding and ischaemic events, with a greater risk of mortality compared to non-HBR patients.
16
Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk
Marco Valgimigli, Enrico Frigoli, Dik Heg et al. · New England Journal of Medicine · 2021 · 544 citations · Full text
Hyun Kuk Kim, Udaya S. Tantry, Sidney C. Smith et al. · Thrombosis and Haemostasis · 2020 · 335 citations · Full text
Marco Valgimigli, Francesco Costa, Yuliya Lokhnygina et al. · European Heart Journal · 2016 · 327 citations · Full text